Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43

Benzinga · 2d ago
Stifel analyst Stephen Willey maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $43.